<DOC>
	<DOCNO>NCT03081819</DOCNO>
	<brief_summary>A Phase I study SH003 evaluate safe dose range patient solid cancer . The first dose group receive SH003 3 week . If adverse event occur less one six participant , dose escalate . The second dose group receive SH003 3 week . If adverse event occur less one six participant , dose escalate . The third dose group receive SH003 3 week .</brief_summary>
	<brief_title>A Phase I Study SH003 Evaluate Safe Dose Range Patients With Solid Cancer</brief_title>
	<detailed_description />
	<criteria>19 year old Patients histologically cytologically confirm solid tumor Patients fail standard treatment , previous chemotherapy radiotherapy , inoperable , refractory , progressive . ECOG score 02 Patients minimum life expectancy 12 week schedule start date study drug Previous treatment surgery radiotherapy , least 4 week since end treatment allow ( patient recover side effect . Patients swallow pill . Patients provide write informed consent participation trial Known hypersensitivity study drug component , include Astragalus membranaceus , Angelica gigas , Trichosanthes Kirilowii Maximowicz Patients preexist cardiac condition : Prior document myocardial infarction within last 6 month Preexisting cardiac failure ( NYHA class IIIIV ) Atrial fibrillation anticoagulant Unstable angina Severe valvulopathy Cardiac angioplasty stenting last 6 month Pregnant lactate female Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety Active uncontrolled infection , include know history AIDS hepatitis B C Any psychological , sociological , geographical condition could potentially interfere compliance study protocol Concurrently receive investigational agent study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>